Treatment of Mycobacterium avium Complex Pulmonary Disease.
- Author:
Yong Soo KWON
1
;
Won Jung KOH
;
Charles L DALEY
Author Information
- Publication Type:Review
- Keywords: Nontuberculous Mycobacteria; Mycobacterium avium Complex; Mycobacterium avium; Mycobacterium intracellulare; Treatment
- MeSH: Amikacin; Body Mass Index; Clofazimine; Consensus; Disease Progression; Ethambutol; Humans; Lung; Lung Diseases; Macrolides; Mycobacterium avium Complex*; Mycobacterium avium*; Mycobacterium*; Nontuberculous Mycobacteria; Nutritional Status; Recurrence; Rifampin; Sputum; Treatment Failure; Treatment Outcome
- From:Tuberculosis and Respiratory Diseases 2019;82(1):15-26
- CountryRepublic of Korea
- Language:English
- Abstract: The pathogen Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacterial pulmonary disease worldwide. The decision to initiate long-term antibiotic treatment is difficult for the physician due to inconsistent disease progression and adverse effects associated with the antibiotic treatment. The prognostic factors for the progression of MAC pulmonary disease are low body mass index, poor nutritional status, presence of cavitary lesion(s), extensive disease, and a positive acid-fast bacilli smear. A regimen consisting of macrolides (clarithromycin or azithromycin) with rifampin and ethambutol has been recommended; this regimen significantly improves the treatment of MAC pulmonary disease and should be maintained for at least 12 months after negative sputum culture conversion. However, the rates of default and disease recurrence after treatment completion are still high. Moreover, treatment failure or macrolide resistance can occur, although in some refractory cases, surgical lung resection can improve treatment outcomes. However, surgical resection should be carefully performed in a well-equipped center and be based on a rigorous risk-benefit analysis in a multidisciplinary setting. New therapies, including clofazimine, inhaled amikacin, and bedaquiline, have shown promising results for the treatment of MAC pulmonary disease, especially in patients with treatment failure or macrolide-resistant MAC pulmonary disease. However, further evidence of the efficacy and safety of these new treatment regimens is needed. Also, a new consensus is needed for treatment outcome definitions as widespread use of these definitions could increase the quality of evidence for the treatment of MAC pulmonary disease.
